ライフサイエンスコーパス: cellular cytotoxicity

1 to those on a healthy diploid cell line for cellular cytotoxicity.

2 virus neutralization, and antibody-dependent cellular cytotoxicity.

3 al antibody, leading to enhanced Fc-mediated cellular cytotoxicity.

4 duction, phagocytosis, and antibody-mediated cellular cytotoxicity.

5 their native counterparts and no significant cellular cytotoxicity.

6 d by viral infection of a host with impaired cellular cytotoxicity.

7 ion rendered tumor cells more susceptible to cellular cytotoxicity.

8 uate eosinophilia through antibody-dependent cellular cytotoxicity.

9 complement activation and antibody-dependent cellular cytotoxicity.

10 sed nuclear translocation of doxorubicin and cellular cytotoxicity.

11 dependent cytotoxicity or antibody-dependent cellular cytotoxicity.

12 tralize SIV isolates, and antibody-dependent cellular cytotoxicity.

13 lls, nor does it diminish antibody-dependent cellular cytotoxicity.

14 ed great in vitro potency and broad spectrum cellular cytotoxicity.

15 o decreases human NK-cell antibody-dependent cellular cytotoxicity.

16 ependent cytotoxicity and antibody-dependent cellular cytotoxicity.

17 an the efficiency of virus neutralization or cellular cytotoxicity.

18 because of their role in antibody-dependent cellular cytotoxicity.

19 rkL is required for efficient NKG2D-mediated cellular cytotoxicity.

20 polymerization inhibition and broad spectrum cellular cytotoxicity.

21 ng center) polarization, and NKG2D-dependent cellular cytotoxicity.

22 s, which in combination reduced Ab-dependent cellular cytotoxicity.

23 proinflammatory chemokines, and significant cellular cytotoxicity.

24 cell-mediated cytotoxicity and Ab-dependent cellular cytotoxicity.

25 s and better induction of antibody-dependent cellular cytotoxicity.

26 and can mediate cell killing by Ab-dependent cellular cytotoxicity.

27 is mediated by a form of antibody-dependent cellular cytotoxicity.

28 ulation of complement activity or diminished cellular cytotoxicity.

29 sis, oxidative burst, and antibody-dependent cellular cytotoxicity.

30 nd properdin and blocking antibody-dependent cellular cytotoxicity.

31 s such as phagocytosis or antibody-dependent cellular cytotoxicity.

32 V-1 isolates and mediated antibody-dependent cellular cytotoxicity.

33 V-1 isolates and mediated antibody-dependent cellular cytotoxicity.

34 ibodies capable of potent antibody-dependent cellular cytotoxicity.

35 mediated cytotoxicity and antibody-dependent cellular cytotoxicity.

36 totoxicity, and increased antibody-dependent cellular cytotoxicity.

37 ecific antibodies through antibody-dependent cellular cytotoxicity.

38 treatment also promoted NK and Ab-dependent cellular cytotoxicity activation, which affected leukemi

39 antibodies with enhanced antibody-dependent cellular cytotoxicity activities.

40 nd thereby decreasing the antibody-dependent cellular cytotoxicity activities.

41 They showed greater Ab-dependent cellular cytotoxicity activity against rituximab-opsoniz

42 bs to V2 and increased both the Ab-dependent cellular cytotoxicity activity and the breadth of neutra

43 amma-receptor binding and antibody-dependent cellular cytotoxicity activity was observed upon decorat

44 amma receptor binding and antibody-dependent cellular cytotoxicity activity, abolished all in vivo ef

45 m binding titer, stronger antibody-dependent cellular cytotoxicity activity, and peak prechallenge an

46 eactive oxygen species or antibody-dependent cellular cytotoxicity activity, but led to up to 47% pha

47 may cooperatively elicit antibody-dependent cellular cytotoxicity activity.

48 Engagement of Ab-dependent cellular cytotoxicity (ADCC) Abs by NK cells leads to ki

49 ding and neutralizing and antibody-dependent cellular cytotoxicity (ADCC) activity after immunization

50 hose capable of mediating antibody-dependent cellular cytotoxicity (ADCC) activity have been postulat

51 of antibodies with potent antibody-dependent cellular cytotoxicity (ADCC) activity in the Thai RV144

52 variant with compromised antibody-dependent cellular cytotoxicity (ADCC) activity strongly inhibited

53 and subsequently modulate antibody-dependent cellular cytotoxicity (ADCC) activity.

54 region of gp120 with high antibody-dependent cellular cytotoxicity (ADCC) activity.

55 ection may correlate with antibody-dependent cellular cytotoxicity (ADCC) activity.

56 iral particles, to direct antibody-dependent cellular cytotoxicity (ADCC) against actively infected c

57 Antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against avian influenza vir

58 e antibodies that mediate antibody-dependent cellular cytotoxicity (ADCC) against heterologous influe

59 C/AIDSVax vaccine induced antibody-dependent cellular cytotoxicity (ADCC) against the Env V2 and cons

60 killer (NK) cell-mediated antibody-dependent cellular cytotoxicity (ADCC) against tumor cells.

61 e potent than hIgG3 in inducing Ab-dependent cellular cytotoxicity (ADCC) and Ab-dependent cellular p

62 body activities mediating antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell

63 V infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phag

64 Antibody-dependent cellular cytotoxicity (ADCC) and complement fixation bot

65 une effector mechanisms such as Ab-dependent cellular cytotoxicity (ADCC) and complement-dependent cy

66 IgG1 b12 mediated strong antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cy

67 ressed cetuximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and their presence correlat

68 To investigate antibody-dependent cellular cytotoxicity (ADCC) as a contributor to Fcgamma

69 In vitro antibody-dependent cellular cytotoxicity (ADCC) assays in the presence of h

70 r phagocytosis (ADCP) and antibody-dependent cellular cytotoxicity (ADCC) assays were performed with

71 ll activation assays, and antibody-dependent cellular cytotoxicity (ADCC) assays.

72 ultiple myeloma cells via antibody-dependent cellular cytotoxicity (ADCC) but did not induce ADCC aga

73 (NK) immune cells mediate antibody-dependent cellular cytotoxicity (ADCC) by aggregating FcgammaRIIIA

74 ave been shown to improve antibody-dependent cellular cytotoxicity (ADCC) by allowing more effective

75 not been shown to inhibit antibody-dependent cellular cytotoxicity (ADCC) by CD16+ NK cells in the pr

76 Antibody-dependent cellular cytotoxicity (ADCC) by immune effector cells ha

77 ffector functions such as antibody-dependent cellular cytotoxicity (ADCC) contributed to the immunity

78 rowing evidence indicates antibody-dependent cellular cytotoxicity (ADCC) contributes to the clinical

79 nalysis, and had enhanced antibody-dependent cellular cytotoxicity (ADCC) effector function relative

80 dies capable of mediating antibody-dependent cellular cytotoxicity (ADCC) effector functions.

81 zing epitopes targeted by antibody-dependent cellular cytotoxicity (ADCC) effector responses.

82 ime point correlated with antibody-dependent cellular cytotoxicity (ADCC) function at the peak immuni

83 ) Env and able to mediate antibody-dependent cellular cytotoxicity (ADCC) have been shown to be prese

84 s a role for HIV-specific antibody-dependent cellular cytotoxicity (ADCC) in controlling viral infect

85 52 functions primarily by antibody-dependent cellular cytotoxicity (ADCC) in vivo, assessment of its

86 bodies and high levels of antibody-dependent cellular cytotoxicity (ADCC) inversely correlate with in

87 Ab-dependent cellular cytotoxicity (ADCC) is believed to be a major a

88 Antibody-dependent cellular cytotoxicity (ADCC) is mediated through the eng

89 Antibody (Ab)-dependent cellular cytotoxicity (ADCC) is thought to potentially p

90 IFN-gamma production and antibody-dependent cellular cytotoxicity (ADCC) is unclear, as are the sign

91 ability of NK cells to mediate Ab-dependent cellular cytotoxicity (ADCC) largely contributes to the

92 Antibody-dependent cellular cytotoxicity (ADCC) may be an important compone

93 Therefore, antibody-dependent cellular cytotoxicity (ADCC) may play a role in cross-pr

94 ibodies (Abs) involved in antibody-dependent cellular cytotoxicity (ADCC) may provide some protection

95 killing of L3 through an antibody-dependent cellular cytotoxicity (ADCC) mechanism.

96 Ab-dependent cellular cytotoxicity (ADCC) mediated by NK cells is reg

97 lement-mediated lysis and antibody-dependent cellular cytotoxicity (ADCC) of transfected cells and pr

98 , CD54 up-regulation, and antibody-dependent cellular cytotoxicity (ADCC) on NK cells from subjects w

99 f HIV-1-infected cells by antibody-dependent cellular cytotoxicity (ADCC) requires the presence of en

100 Ab-dependent cellular cytotoxicity (ADCC) responses are of growing in

101 well as neutralizing and antibody-dependent cellular cytotoxicity (ADCC) responses in plasma and mil

102 utralizing antibodies and antibody-dependent cellular cytotoxicity (ADCC) responses.

103 of potentially protective antibody-dependent cellular cytotoxicity (ADCC) responses.

104 XmAb5592 increased antibody-dependent cellular cytotoxicity (ADCC) several fold relative to th

105 nt cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) through the antibody Fc reg

106 rum antienvelope avidity, antibody-dependent cellular cytotoxicity (ADCC) titers, and percent antibod

107 ing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to eliminate infected cells

108 MPORTANCE Mobilization of antibody-dependent cellular cytotoxicity (ADCC) to eliminate reactivated la

109 y infected cells mobilize antibody-dependent cellular cytotoxicity (ADCC) to eliminate the HIV-1-infe

110 ch interest in the potential of Ab-dependent cellular cytotoxicity (ADCC) to slow disease progression

111 rts proposed a role for NK cell Ab-dependent cellular cytotoxicity (ADCC) triggered via FcgammaR-IIIA

112 n the secondary analysis, antibody-dependent cellular cytotoxicity (ADCC) was another inverse correla

113 Previously, Ab-dependent cellular cytotoxicity (ADCC) was significantly correlate

114 ctor functions, including antibody-dependent cellular cytotoxicity (ADCC) which is mediated in part t

115 hat modulate HIV-specific antibody-dependent cellular cytotoxicity (ADCC) will help in understanding

116 tibody-opsonized cells by antibody-dependent cellular cytotoxicity (ADCC), a reaction generally consi

117 ll line-based assays, including Ab-dependent cellular cytotoxicity (ADCC), Ab-dependent cell-mediated

118 plement-dependent cytotoxicity, Ab-dependent cellular cytotoxicity (ADCC), Ab-dependent cellular phag

119 virus-infected target cells by Ab-dependent cellular cytotoxicity (ADCC), an immune mechanism that h

120 t-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (ADCC), and apoptotic mechanisms o

121 gp120 and V1V2 responses, antibody-dependent cellular cytotoxicity (ADCC), and low-titer tier 1B and

122 The MAbs mediated antibody-dependent cellular cytotoxicity (ADCC), and mice that received the

123 nding titers, substantial antibody-dependent cellular cytotoxicity (ADCC), and modest antibody-depend

124 killer (NK)-cell-mediated antibody-dependent cellular cytotoxicity (ADCC), but little is known about

125 antitumor effects include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cell

126 ctive effects by means of antibody-dependent cellular cytotoxicity (ADCC), in which virus-specific an

127 ng tier 1 neutralization, antibody-dependent cellular cytotoxicity (ADCC), infected cell binding, and

128 atory agent that enhances antibody-dependent cellular cytotoxicity (ADCC), is currently being investi

129 also a potent mediator of antibody-dependent cellular cytotoxicity (ADCC), lysing B-CLL cells more ef

130 XmAb5574 mediates potent antibody-dependent cellular cytotoxicity (ADCC), modest direct cytotoxicity

131 b that possesses enhanced antibody-dependent cellular cytotoxicity (ADCC), nonantigenic glycosylation

132 ivity, antibodies mediate antibody-dependent cellular cytotoxicity (ADCC), the killing of an antibody

133 nsitize infected cells to antibody-dependent cellular cytotoxicity (ADCC), we treated cells with the

134 n significantly decreases antibody-dependent cellular cytotoxicity (ADCC), whereas terminal alpha2,6-

135 One such mechanism is antibody-dependent cellular cytotoxicity (ADCC), whereby host antibodies bi

136 leukocytes (PMNs) mediate antibody-dependent cellular cytotoxicity (ADCC), which is increased by the

137 to drastic enhancement of antibody-dependent cellular cytotoxicity (ADCC), while terminal alpha2,6-si

138 influenza virus-specific antibody-dependent cellular cytotoxicity (ADCC)-activating antibodies are r

139 al killer (NK) cells, via antibody-dependent cellular cytotoxicity (ADCC)-like mechanism, increase IF

140 neage induces HA-specific antibody-dependent cellular cytotoxicity (ADCC)-mediating antibodies.

141 tion and NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

142 ing regulatory T cells by antibody-dependent cellular cytotoxicity (ADCC).

143 endent processes, such as antibody-dependent cellular cytotoxicity (ADCC).

144 for its role in mediating antibody-dependent cellular cytotoxicity (ADCC).

145 ral mechanisms, including antibody-dependent cellular cytotoxicity (ADCC).

146 to its ability to mediate antibody-dependent cellular cytotoxicity (ADCC).

147 ability of mAbs to induce antibody dependent cellular cytotoxicity (ADCC).

148 s by antibodies mediating antibody-dependent cellular cytotoxicity (ADCC).

149 et cells through the process of Ab-dependent cellular cytotoxicity (ADCC).

150 g and rituximab-mediated, antibody-dependent cellular cytotoxicity (ADCC).

151 c receptor (FcR)-mediated antibody-dependent cellular cytotoxicity (ADCC).

152 xert cytotoxic effects is antibody-dependent cellular cytotoxicity (ADCC).

153 hanism of action involves antibody-dependent cellular cytotoxicity (ADCC).

154 ent cell lysis (CDC), and antibody-dependent cellular cytotoxicity (ADCC).

155 lity of infected cells to antibody-dependent cellular cytotoxicity (ADCC).

156 tion and NK-cell-mediated antibody-dependent cellular cytotoxicity (ADCC).

157 oengineered for augmented antibody-dependent cellular cytotoxicity (ADCC).

158 ntibodies able to mediate antibody-dependent cellular cytotoxicity (ADCC).

159 ated from latency through antibody-dependent cellular cytotoxicity (ADCC).

160 o destroy Ab-coated targets via Ab-dependent cellular cytotoxicity (ADCC).

161 xpressing cancer cells by antibody-dependent cellular cytotoxicity (ADCC).

162 heir impact on NK cell-mediated Ab-dependent cellular cytotoxicity (ADCC).

163 t CD4i antibodies mediate antibody-dependent cellular cytotoxicity (ADCC).

164 ent cytotoxicity (CDC) or antibody-dependent cellular-cytotoxicity (ADCC), so as to reduce reliance o

165 atural killer (NK) cells (antibody-dependent cellular cytotoxicity [ADCC]) or complement (complement-

166 nnate immune responses (termed "Ab-dependent cellular cytotoxicity [ADCC]-mediating Abs"), may assist

167 ce of a cross-linker, and antibody-dependent cellular cytotoxicity against B-cell leukemia/lymphoma c

168 l direct cytotoxicity and antibody-dependent cellular cytotoxicity against hematopoietic and nonhemat

169 residues mediated higher antibody-dependent cellular cytotoxicity against human tumor cells.

170 ed antibodies conferred complement-dependent cellular cytotoxicity against MCF-7 and OVCAR-5 cells.

171 Fc form (Pr20M) directed antibody-dependent cellular cytotoxicity against PRAME+HLA-A2+ leukemia cel

172 with concurrent enhanced antibody-dependent cellular cytotoxicity against rituximab-coated CLL cells

173 delta T cells can perform antibody-dependent cellular cytotoxicity against stromal cells coated with

174 1(-/-) splenocytes can mediate Ab-dependent cellular cytotoxicity against this tumor in the presence

175 cific antibodies mediated antibody-dependent cellular cytotoxicity against tumor cells from human col

176 a are capable of inducing antibody-dependent cellular cytotoxicity, an activity not observed for (CHO

177 dings suggest that, in addition to mediating cellular cytotoxicity and apoptosis, the anti-tumor acti

178 capable of both achieving antibody-dependent cellular cytotoxicity and blocking of IL-1 signaling as

179 antibodies display robust antibody-dependent cellular cytotoxicity and CD4-dependent virion capture a

180 functions to F(ab')(2) in both Ab-dependent cellular cytotoxicity and complement-dependent cytotoxic

181 of neuroblastoma cells by antibody-dependent cellular cytotoxicity and complement-dependent cytotoxic

182 The antibody-dependent cellular cytotoxicity and complement-dependent cytotoxic

183 cted cells by Fc-mediated antibody-dependent cellular cytotoxicity and complement-dependent cytotoxic

184 L-15 genes was able to increase Ab-dependent cellular cytotoxicity and complement-dependent lysis of

185 responses were driven by antibody-dependent cellular cytotoxicity and complement-directed cytotoxici

186 peutic antibody including antibody-dependent cellular cytotoxicity and complement-mediated cell lysis

187 diated both AQP4-directed antibody-dependent cellular cytotoxicity and complement-mediated lysis.

188 have lower and slower replication, and lower cellular cytotoxicity and cytokine and/or chemokine prod

189 -type lectin-like receptor (CTLR) triggering cellular cytotoxicity and cytokine secretion upon high-a

190 antibody had no impact on antibody-dependent cellular cytotoxicity and did not change the affinity of

191 BVDV by AZA occurred at lower doses than the cellular cytotoxicity and did not depend on cytotoxicity

192 en fatal disorder characterized by defective cellular cytotoxicity and hyperinflammation, and the onl

193 7H6-specific BiTEs direct T cells to mediate cellular cytotoxicity and IFN-gamma secretion upon cocul

194 et for cetuximab-mediated antibody-dependent cellular cytotoxicity and in vivo elimination.

195 s and have disadvantages of variable uptake, cellular cytotoxicity and loss of nanoparticles on cell

196 lity to cetuximab-induced antibody-dependent cellular cytotoxicity and occurred independently of KRAS

197 ffector functions such as antibody-dependent cellular cytotoxicity and phagocytosis.

198 ls were resistant to both antibody-dependent cellular cytotoxicity and signaling-induced cell death.

199 cR (FcgammaRIIIa) that mediates Ab-dependent cellular cytotoxicity and the production of immune modul

200 macrophages that mediate antibody-dependent cellular cytotoxicity and/or trigger cross-linking induc

201 plement-dependent cytotoxicity, Ab-dependent cellular cytotoxicity, and Ab-dependent cellular phagocy

202 pendent FcgammaR-mediated antibody-dependent cellular cytotoxicity, and by direct complement-mediated

203 mab to mediate apoptosis, antibody-dependent cellular cytotoxicity, and complement-dependent cytotoxi

204 drogenase (LDH) concentration as a marker of cellular cytotoxicity, and cytokine and/or chemokine sec

205 s (antibody dependent cellular phagocytosis, cellular cytotoxicity, and cytokine release).

206 unctions, such as phagocytosis, Ab-dependent cellular cytotoxicity, and cytokine release.

207 ets through direct lysis, antibody-dependent cellular cytotoxicity, and production of chemokines and

208 responses such as phagocytosis, Ab-dependent cellular cytotoxicity, and respiratory burst.

209 nnate immunity, enhancing antibody dependent cellular cytotoxicity, and serving as potent vaccine adj

210 ys, such as phagocytosis, antibody-dependent cellular cytotoxicity, and the recruitment and activatio

211 shown to be sensitive to antibody-dependent cellular cytotoxicity, and their in vitro proliferation

212 n of Vav-2 in cytotoxic lymphocytes enhances cellular cytotoxicity, and this enhancement requires a f

213 ization, complement activation, Ab-dependent cellular cytotoxicity, and toxin/viral neutralization.

214 ding apoptosis induction, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phago

215 t-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, antibody-dependent cellular phago

216 We examined the effects of MGd on cellular cytotoxicity, apoptosis, reactive oxygen specie

217 ignaling mechanisms governing NKG2D-mediated cellular cytotoxicity are unknown.

218 erative activity was established in an A2780 cellular cytotoxicity assay in which 21 showed an IC(50)

219 Antibody-dependent cellular cytotoxicity assays using purified peripheral b

220 Candidates were characterized in cellular cytotoxicity assays with Chinese hamster ovary

221 protective antigen proteins were analyzed by cellular cytotoxicity assays, and their interactions wit

222 n by Fc alpha RI as measured in Ab-dependent cellular cytotoxicity assays.

223 Fc domain that eliminates antibody-dependent cellular cytotoxicity at clinically relevant doses to pr

224 enhanced NK cell activation and Ab-dependent cellular cytotoxicity at high Ab concentrations.

225 ffector mechanisms such as antibody-directed cellular cytotoxicity, but they can also be induced by a

226 in the treatment of malignant glioma, causes cellular cytotoxicity by forming O(6)-methylguanine addu

227 sical complement pathway, antibody-dependent cellular cytotoxicity by innate immune cell subsets also

228 resulting from mutation in genes involved in cellular cytotoxicity can be crucial.

229 ssay, but demonstrated significantly reduced cellular cytotoxicity compared to epothilone B.

230 ependent cytotoxicity and antibody-dependent cellular cytotoxicity compared with rituximab.

231 The 20-2b shows enhanced antibody-dependent cellular cytotoxicity compared with veltuzumab but lacks

232 ector functions including antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity

233 rrelation suggesting a biochemical basis for cellular cytotoxicity could be supported.

234 rted to display increased antibody-dependent cellular cytotoxicity, demonstrates that glycan engineer

235 viously, we demonstrated that NKp65-mediated cellular cytotoxicity depends on tyrosine 7, located in

236 or mechanism of action is antibody-dependent cellular cytotoxicity (eg, trastuzumab in breast cancer

237 ngineered Fc variants for antibody-dependent cellular cytotoxicity enhancement could be embedded in m

238 ment-dependent cytotoxicity and Ab-dependent cellular cytotoxicity favored a membrane-proximal epitop

239 The in vivo half-life, antibody-dependent cellular cytotoxicity function, and binding ability to F

240 of C15 cells in in vitro antibody-dependent cellular cytotoxicity has been observed by immune sera.

241 F) that activates this critical regulator of cellular cytotoxicity has not been identified.

242 on and mediates effective antibody-dependent cellular cytotoxicity in a variety of tumor cells.

243 tion of redox balance by MGd would result in cellular cytotoxicity in myeloma.

244 ese include activation of antibody-dependent cellular cytotoxicity, inhibition of extracellular domai

245 killer (NK) cell-mediated antibody-dependent cellular cytotoxicity involving FcgammaRIIIa (CD16) like

246 Cellular cytotoxicity is essential for the elimination o

247 Nevertheless, in CLL, Ab-dependent cellular cytotoxicity is relatively impaired by the low

248 Cellular cytotoxicity is the hallmark of NK cells mediat

249 likely be ascribed to the antibody-dependent cellular cytotoxicity machinery because IL-27 successful

250 umor clearance other than antibody-dependent cellular cytotoxicity may be more important.

251 and eliminates them through an Ab-dependent cellular cytotoxicity mechanism in vitro.

252 ction of apoptosis, or possibly Ab-dependent cellular cytotoxicity mediated against tumor targets.

253 alternatives: the first, antibody-dependent cellular cytotoxicity mediated by FcRI- or FcRIII-expres

254 K cells are largely involved in Ab-dependent cellular cytotoxicity mediated by therapeutic mAbs, such

255 tal Ab in its ability to effect Ab-dependent cellular cytotoxicity-mediated tumor cell lysis.

256 l killer cells to enhance antibody-dependent cellular cytotoxicity, mediates complement-dependent cyt

257 inding, neutralizing, and antibody-dependent cellular cytotoxicity-mediating antibodies against the p

258 ved from broadly binding, antibody-dependent cellular cytotoxicity-mediating antibodies known to bind

259 owed Galcer blocking, the antibody-dependent cellular cytotoxicity-mediating CH38 IgG and its natural

260 s the potential role that antibody-dependent cellular cytotoxicity might play in antilatency cure app

261 dy-coated tachyzoites nor antibody-dependent cellular cytotoxicity nor antibody-and-complement-depend

262 olymerization, suggesting that inhibition of cellular cytotoxicity occurs through an early dephosphor

263 The 3.2G1 TCRm-mediated CDC and Ab-dependent cellular cytotoxicity of a human breast carcinoma line i

264 D200-G1 Abs efficiently mediate Ab-dependent cellular cytotoxicity of activated T cells, critical cel

265 immuno-Doxil(R) preparation showed increased cellular cytotoxicity of B16-F10, HeLa and MCF-7 cells w

266 ependent cytotoxicity and antibody-dependent cellular cytotoxicity of CD20-positive human B cells.

267 owth and induces in vitro antibody-dependent cellular cytotoxicity of human neuroblastoma-derived cel

268 sis provides the biochemical explanation for cellular cytotoxicity of methylating agents.

269 f RANKL with induction of antibody-dependent cellular cytotoxicity of natural killer (NK) cells again

270 of S. aureus by neutrophils and Ab-dependent cellular cytotoxicity of tumor cells by both neutrophils

271 , as was the ability to block ricin-mediated cellular cytotoxicity on human and murine cell lines.

272 tion through mechanisms that did not involve cellular cytotoxicity or apoptosis.

273 imab, hLL1 did not induce antibody-dependent cellular cytotoxicity or complement-mediated cytotoxicit

274 of nitric oxide (NO) as a potent mediator of cellular cytotoxicity or signaling.

275 e of antibodies to induce antibody-dependent cellular cytotoxicity or to block iKIRs, or by transduct

276 ct cell death, NK cell-mediated Ab-dependent cellular cytotoxicity, or complement-dependent cytotoxic

277 mice with specific genetic defects in immune cellular cytotoxicity (perforin knockout mice) and costi

278 Ab-dependent cellular cytotoxicity, phagocytosis, and Ag presentation

279 nt effector functions including Ab-dependent cellular cytotoxicity, phagocytosis, and complement fixa

280 ty (virus neutralization, antibody-dependent cellular cytotoxicity, phagocytosis, and virion capture)

281 through the induction of antibody-dependent cellular cytotoxicity, promotion of antibody-targeted cr

282 a manner associated with antibody-dependent cellular cytotoxicity rather than EGFR pathway inhibitio

283 odies, and high levels of antibody-dependent cellular cytotoxicity responses and HIV-1-neutralizing a

284 Moreover, Ab-dependent cellular cytotoxicity responses inversely correlated wit

285 binding during phagocytosis and Ab-dependent cellular cytotoxicity, resulting in a phenotype similar

286 Rituximab-mediated cellular cytotoxicity (RMCC) was assessed by lactate deh

287 rotection correlated with antibody-dependent cellular cytotoxicity specific for CD4-induced epitopes,

288 pression, which may be important to regulate cellular cytotoxicity that could otherwise lead to cell

289 t that exhibited enhanced antibody-dependent cellular cytotoxicity, the lack of fucose was synergisti

290 ely less efficient in mediating Ab-dependent cellular cytotoxicity through either receptor.

291 All the peptide Abs showed Ab-dependent cellular cytotoxicity to varying degrees with the 266-29

292 lls, the key mediators of antibody-dependent cellular cytotoxicity, to human AMR in allotransplantati

293 mor models by stimulating antibody-dependent cellular cytotoxicity toward tumor vessels.

294 t in cytotoxicity because antibody-dependent cellular cytotoxicity was intact.

295 Antibody-dependent cellular cytotoxicity was not required for larval killin

296 isorganization, caveolin-1 inactivation, and cellular cytotoxicity were inhibited when target cells w

297 Thirty kinases showed significant cellular cytotoxicity when depleted, with loss of the ce

298 ependent cytotoxicity and antibody-dependent cellular cytotoxicity, which suggests that IdeS might be

299 tibodies did not manifest antibody-dependent cellular cytotoxicity with NOD/SCID splenocytes that vir

300 might sometimes have mutations that affected cellular cytotoxicity without affecting pigmentation.